Urinary level of ca19-9 as a tumor marker in urothelial carcinoma of the bladder

Urology Journal

Volumn 8, Issue 3, 2011, Pages 203-208

  Pal, Keya ^a   Roy, Suparna ^a   Mondal, Samim Ali ^a   Chatterjee, Uttara ^a   Tiwari, Punit ^b   Bera, Malay ^b  

^a IPGME and R ^*  (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Ca 19 9 antigen; Tumor markers; Urinalysis; Urinary bladder neoplasms

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ARTICLE; BLADDER TUMOR; CASE CONTROL STUDY; HUMAN; MIDDLE AGED; TRANSITIONAL CELL CARCINOMA; URINE;

CA-19-9 ANTIGEN; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84855544359     PISSN: 17351308     EISSN: 1735546X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. American Cancer Society. Cancer Facts and Figure 2005. Atlanta.
2. Morrison AS. Advances in the etiology of urothelial cancer. Urol Clin North Am. 1984;11:557-66.
3. Burch JD, Rohan TE, Howe GR, et al. Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer. 1989;44:622-8.
4. Whelan P, Britton JP, Dowell AC. Three year Follow up of Bladder Tumours found on Screening. Br J Urol. 1993;72:893-6.
5. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173-9.
6. Rodriguez-Rubio F, Sanz G, Garrido S, Sanchez C, Estudillo F. Patient tolerance during outpatient flexible cystoscopy--a prospective, randomized, double-blind study comparing plain lubrication and lidocaine gel. Scand J Urol Nephrol. 2004;38:477-80.
7. Almallah YZ, Rennie CD, Stone J, Lancashire MJR. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation* 1. Urology. 2000;56:37-9.
8. Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol. 1993;150:1751-6.
9. Rife CC, Farrow GM, Utz DC. Urine cytology of transitional cell neoplasms. Urol Clin North Am. 1979;6:599-612.
10. Sherman AB, Koss LG, Adams SE. Interobserver and intraobserver differences in the diagnosis of urothelial cells. Comparison with classification by computer. Anal Quant Cytol. 1984;6:112-20.
11. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986;90:343-9.
12. Saraswati A, Malati T. Superiority of CA 125 over CA 19-9 and CEA for epithelial ovarian malignancies Indian J Clin Biochem. 1995;10:23-8.
13. Burke DM, Shackley DC, O'Reilly PH. The communitybased morbidity of flexible cystoscopy. BJU Int. 2002;89:347-9.
14. Bigbee W, Herberman RB. Tumor markers and immunodiagnosis. 6 ed. Hamilton, Ontario: BC Decker; 2003.
15. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol. 2008;53:909-16.
16. Kau SY, Shyr YM, Su CH, Wu CW, Lui WY. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg. 1999;188: 415-20.
17. Taylor B. Carcinoma of the head of the pancreas versus chronic pancreatitis: diagnostic dilemma with significant consequences. World J Surg. 2003;27:1249-57.
18. Hegele A, Mecklenburg V, Varga Z, Olbert P, Hofmann R, Barth P. CA19. 9 and CEA in Transitional Cell Carcinoma of the Bladder: Serological and Immunohistochemical Findings. Anticancer research. 2010;30:5195.
19. Vriesema JL, Poucki MH, Kiemeney LA, Witjes JA. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis. Urology. 2000;56:793-7
20. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 2005;47:736-48.
21. Nagao K, Itoh Y, Fujita K, Fujime M. Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes. Int J Urol. 2007;14:795-9.
22. Droller MJ. Current concepts of tumor markers in bladder cancer. Urol Clin North Am. 2002;29:229-34.
23. Maestranzi S, Przemioslo R, Mitchell H, Sherwood R. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem. 1998;35:99.
24. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology. 2006;67:25-33; discussion -4.
25. Nam RK, Redelmeier DA, Spiess PE, Sampson HA, Fradet Y, Jewett MA. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urol. 2000;163:752-7.